Sun Pharmaceutical Industries Limited — Others, 26-11-2024: Action(s) taken or orders passed

Sun Pharmaceutical Industries Limited and its subsidiary, Sun Pharma Laboratories Limited, have received a significant order from the Customs authority involving the imposition of fines and penalties due to re-classification of imported products. Specifically, the company faces a redemption fine of ₹27 crore and a penalty of ₹125.86 crore; Sun Pharma Laboratories is subject to a redemption fine of ₹900 crore and a penalty of ₹478.94 crore. Despite this regulatory action, the company stated that there is no material impact on its financial operations. Investors may view this situation as posing potential risks, but the absence of a material impact suggests a neutral sentiment may prevail in the market.